- Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.
Dalgleish AG, Stebbing J, Adamson DJ, Arif SS, Bidoli P, Chang D, Cheeseman S, Diaz-Beveridge R, Fernandez-Martos C, Glynne-Jones R, Granetto C, Massuti B, McAdam K, McDermott R, Martín AJ, Papamichael D, Pazo-Cid R, Vieitez JM, Zaniboni A, Carroll KJ, Wagle S, Gaya A, Mudan SS.
Br J Cancer. 2016 Sep 6. doi: 10.1038/bjc.2016.271.
- Extended Survival after Complete Pathological Response in Metastatic Pancreatic Ductal Adenocarcinoma Following Induction Chemotherapy, Chemoradiotherapy, and a Novel Immunotherapy Agent, IMM-101.
Costa Neves M, Giakoustidis A, Stamp G, Gaya A, Mudan S.
Cureus. 2015 Dec 26;7(12):e435. doi: 10.7759/cureus.435.
- Tumor Biology: Is It Time to Redefine Unresectability? An Extraordinary Case of Gastroesophageal Junctional Adenocarcinoma.
Gaya A, Giakoustidis A, Winslet M, Mudan S.
Cureus. 2015 Dec 21;7(12):e420. doi: 10.7759/cureus.420.
- Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum.
Glynne-Jones R, Hava N, Goh V, Bosompem S, Bridgewater J, Chau I, Gaya A, Wasan H, Moran B, Melcher L, MacDonald A, Osborne M, Beare S, Jitlal M, Lopes A, Hall M, West N, Quirke P, Wong WL, Harrison M; Bacchus investigators.
BMC Cancer. 2015 Oct 23;15:764. doi: 10.1186/s12885-015-1764-1.
- The Concept of Hormesis in Cancer Therapy – Is Less More?
Gaya A, Akle CA, Mudan S, Grange J.
Cureus. 2015 Apr 2;7(4):e261. doi: 10.7759/cureus.261. eCollection 2015 Apr. Review.
- Best of the Radiosurgery Society® Scientific Meeting 2014: stereotactic radiosurgery/stereotactic body radiotherapy treatment of extracranial and intracranial lesions.
Mahadevan A, Bucholz R, Gaya AM, Kresl JJ, Mantz C, Minnich DJ, Muacevic A, Medbery C 3rd, Yang J, Caglar HB, Davis JN.
Future Oncol. 2014 Dec;10(15):2307-10. doi: 10.2217/fon.14.168.
- Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial.
Wasan H, Meade AM, Adams R, Wilson R, Pugh C, Fisher D, Sydes B, Madi A, Sizer B, Lowdell C, Middleton G, Butler R, Kaplan R, Maughan T; COIN-B investigators.
Lancet Oncol. 2014 May;15(6):631-9. doi: 10.1016/S1470-2045(14)70106-8. Epub 2014 Apr 3.
- Rectal tumour volume (GTV) delineation using T2-weighted and diffusion-weighted MRI: Implications for radiotherapy planning.
Regini F, Gourtsoyianni S, Cardoso De Melo R, Charles-Edwards GD, Griffin N, Parikh J, Rottenberg G, Leslie M, Gaya A, Goh V.
Eur J Radiol. 2014 May;83(5):768-72. doi: 10.1016/j.ejrad.2014.02.007. Epub 2014 Feb 25.
- Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer.
Yip C, Goh V, Davies A, Gossage J, Mitchell-Hay R, Hynes O, Maisey N, Ross P, Gaya A, Landau DB, Cook GJ, Griffin N, Mason R.
Eur Radiol. 2014 May;24(5):998-1005. doi: 10.1007/s00330-014-3110-4. Epub 2014 Feb 18.
- Cardiac complications after radical radiotherapy.
Martinou M, Gaya A.
Semin Oncol. 2013 Apr;40(2):178-85. doi: 10.1053/j.seminoncol.2013.01.007. Review.
- Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours.
Goldsmith C, Gaya A.
Cancer Imaging. 2012 Sep 28;12:351-60.
- A preclinical and clinical review of aflibercept for the management of cancer.
Gaya A, Tse V.
Cancer Treat Rev. 2012 Aug;38(5):484-93. doi: 10.1016/j.ctrv.2011.12.008. Epub 2012 Jan 20. Review.
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP; MRC COIN Trial Investigators.
Lancet. 2011 Jun 18;377(9783):2103-14. doi: 10.1016/S0140-6736(11)60613-2. Epub 2011 Jun 5.
- Anti-angiogenesis therapies: their potential in cancer management.
Eichholz A, Merchant S, Gaya AM.
Onco Targets Ther. 2010 Jun 24;3:69-82.
- An analysis of intraoperative versus post-operative dosimetry with CT, CT-MRI fusion and XMR for the evaluation of permanent prostate brachytherapy implants.
Acher P, Puttagunta S, Rhode K, Morris S, Kinsella J, Gaya A, Dasgupta P, Deehan C, Beaney R, Popert R, Keevil S.
Radiother Oncol. 2010 Aug;96(2):166-71. doi: 10.1016/j.radonc.2010.06.003. Epub 2010 Jul 6.
- A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.
Rustin GJ, Shreeves G, Nathan PD, Gaya A, Ganesan TS, Wang D, Boxall J, Poupard L, Chaplin DJ, Stratford MR, Balkissoon J, Zweifel M.
Br J Cancer. 2010 Apr 27;102(9):1355-60. doi: 10.1038/sj.bjc.6605650. Epub 2010 Apr 13.
- Stereotactic body radiotherapy: a review.
Martin A, Gaya A.
Clin Oncol (R Coll Radiol). 2010 Apr;22(3):157-72. doi: 10.1016/j.clon.2009.12.003. Epub 2010 Jan 25. Review.
- A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.
Meyer T, Gaya AM, Dancey G, Stratford MR, Othman S, Sharma SK, Wellsted D, Taylor NJ, Stirling JJ, Poupard L, Folkes LK, Chan PS, Pedley RB, Chester KA, Owen K, Violet JA, Malaroda A, Green AJ, Buscombe J, Padhani AR, Rustin GJ, Begent RH.
Clin Cancer Res. 2009 Jul 1;15(13):4484-92. doi: 10.1158/1078-0432.CCR-09-0035. Epub 2009 Jun 23.
- Relationship between human tumour angiogenic profile and combretastatin-induced vascular shutdown: an exploratory study.
Gaya A, Daley F, Taylor NJ, Tozer G, Qureshi U, Padhani A, Pedley RB, Begent R, Wellsted D, Stirling JJ, Rustin G.
Br J Cancer. 2008 Jul 22;99(2):321-6. doi: 10.1038/sj.bjc.6604426. Epub 2008 Jul 8.
- A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study.
Hughes S, Liong J, Miah A, Ahmad S, Leslie M, Harper P, Prendiville J, Shamash J, Subramaniam R, Gaya A, Spicer J, Landau D.
J Thorac Oncol. 2008 Jun;3(6):648-51. doi: 10.1097/JTO.0b013e3181757a60.
- Comparison of combined x-ray radiography and magnetic resonance (XMR) imaging-versus computed tomography-based dosimetry for the evaluation of permanent prostate brachytherapy implants.
Acher P, Rhode K, Morris S, Gaya A, Miquel M, Popert R, Tham I, Nichol J, McLeish K, Deehan C, Dasgupta P, Beaney R, Keevil SF.
Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1518-25. doi: 10.1016/j.ijrobp.2008.03.065. Epub 2008 May 29.
- Cross-over response to erlotinib of brain metastatic disease from bronchial adenocarcinoma after gefitinib failure, and an unusual rash.
Walther JC, Khorshid M, Gaya A, Plowman PN.
Clin Oncol (R Coll Radiol). 2006 Oct;18(8):637-9. No abstract available.
- Breast cancer (metastatic).
Stebbing J, Crane J, Gaya A.
Clin Evid. 2006 Jun;(15):2331-59. Review. No abstract available.
- Linear quadratic modeling of increased late normal-tissue effects in special clinical situations.
Jones B, Dale RG, Gaya AM.
Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):948-53.
- Clinical Progress in Tumour Vascular Disrupting Therapies.
Gaya AM , Rustin GJS
Chapter 17 of ‘Vascular Targeted Therapies In Oncology’; pp 305 – 322. Editor Siemann D ; Publisher, Wiley 2006. ISBN 0-470-01294-3
- A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy.
Bower M, Gazzard B, Mandalia S, Newsom-Davis T, Thirlwell C, Dhillon T, Young AM, Powles T, Gaya A, Nelson M, Stebbing J.
Ann Intern Med. 2005 Aug 16;143(4):265-73. Erratum in: Ann Intern Med. 2006 Apr 18;144(8):620.
- Vascular disrupting agents: a new class of drug in cancer therapy.
Gaya AM, Rustin GJ.
Clin Oncol (R Coll Radiol). 2005 Jun;17(4):277-90. Review.
- Cardiac complications of radiation therapy.
Gaya AM, Ashford RF.
Clin Oncol (R Coll Radiol). 2005 May;17(3):153-9. Review.
- Right Ventricular Outflow Obstruction Secondary To Myocardial Metastases From Colorectal Cancer.
Gaya AM, Randle A , Ashford RFU
Clinical Oncology 2005 ; 17 (1) : 70 – 71
- Pegylated liposomal doxorubicin (Caelyx) in recurrent ovarian cancer.
Stebbing J, Gaya A.
Cancer Treat Rev. 2002 Apr;28(2):121-5. Review.
- The use of temozolomide in recurrent malignant gliomas.
Gaya A, Rees J, Greenstein A, Stebbing J.
Cancer Treat Rev. 2002 Apr;28(2):115-20. Review.
- The evidence-based use of induction chemotherapy in breast cancer.
Stebbing J J, Gaya A.
Breast Cancer. 2001;8(1):23-37. Review.
- Perforated diverticulitis following extra-abdominal surgery.
Gaya AM, Chisholm EM, Scott HJ, Donaldson DR.
Postgrad Med J. 1997 Nov;73(865):739-40.